Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:GILD
- CUSIP: 37555810
- Web: www.gilead.com
Capitalization:- Market Cap: $96.38425 billion
- Outstanding Shares: 1,306,728,000
Average Prices:- 50 Day Moving Avg: $68.32
- 200 Day Moving Avg: $68.63
- 52 Week Range: $63.76 - $88.85
P/E:- Trailing P/E Ratio: 7.86
- Foreward P/E Ratio: 10.36
- P/E Growth: -1.04
Sales & Book Value:- Annual Revenue: $29.1 billion
- Price / Sales: 3.34
- Book Value: $15.64 per share
- Price / Book: 4.76
Dividend:- Annual Dividend: $2.08
- Dividend Yield: 2.8%
Profitability:- EBIDTA: $18.24 billion
- Net Margins: 43.42%
- Return on Equity: 76.64%
- Return on Assets: 25.55%
Debt:- Debt-to-Equity Ratio: 1.26%
- Current Ratio: 2.59%
- Quick Ratio: 2.41%
Misc:- Average Volume: 8.63 million shs.
- Beta: 1.2
- Short Ratio: 1.29
Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences announced a quarterly dividend on Tuesday, May 2nd. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.80%. The ex-dividend date is Wednesday, June 14th. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Tuesday, May, 2nd. The company reported $2.20 EPS for the quarter, topping the Zacks' consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. View Gilead Sciences' Earnings History.
Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?
26 brokers have issued 1-year target prices for Gilead Sciences' stock. Their predictions range from $65.50 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $80.32 in the next year. View Analyst Ratings for Gilead Sciences.
What are analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. According to Zacks Investment Research, "Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales." (7/18/2017)
- 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
- 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
- 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
Are investors shorting Gilead Sciences?
Gilead Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totalling 13,658,785 shares, an increase of 15.7% from the June 15th total of 11,804,652 shares. Based on an average trading volume of 13,707,757 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.1% of the company's shares are sold short.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene Corporation (CELG), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO) and Agios Pharmaceuticals (AGIO).
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- John C. Martin Ph.D., Executive Chairman of the Board
- John F. Milligan Ph.D., Chief Executive Officer, Director
- Robin L. Washington, Chief Financial Officer, Executive Vice President
- Kevin B. Young, Chief Operating Officer
- Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
- Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
- James R. Meyers, Executive Vice President - Worldwide Commercial Operations
- John F. Cogan Jr. Ph.D., Lead Independent Director
- Kelly A. Kramer, Independent Director
- Kevin E. Lofton, Independent Director
Who owns Gilead Sciences stock?
Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.42%), State Treasurer State of Michigan (0.24%), Swedbank (0.17%), PGGM Investments (0.11%), AMF Pensionsforsakring AB (0.09%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?
Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., NN Investment Partners Holdings N.V., First Quadrant L P CA, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Russell Investments Group Ltd., Beech Hill Advisors Inc., TNB Financial and Sit Investment Associates Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.
Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?
Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Aperio Group LLC, Foundation Resource Management Inc., Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., US Bancorp DE, National Pension Service and Exane Asset Management. View Insider Buying and Selling for Gilead Sciences.
How do I buy Gilead Sciences stock?
Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of Gilead Sciences stock can currently be purchased for approximately $74.39.
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 11 Hold Ratings, 14 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.62) |
| Consensus Price Target: | $80.32 (7.98% upside) |
Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/25/2017 | Leerink Swann | Reiterated Rating | Hold | $74.00 | Low |  |
| 7/21/2017 | BMO Capital Markets | Reiterated Rating | Hold | $72.00 | Low | |
| 7/13/2017 | Robert W. Baird | Reiterated Rating | Outperform | $87.00 | Low | |
| 7/11/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | | Low | |
| 7/11/2017 | Jefferies Group LLC | Reiterated Rating | Hold -> Hold | $80.00 | Low | |
| 7/5/2017 | Cowen and Company | Reiterated Rating | Outperform | $90.00 | Low | |
| 7/4/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $82.00 | Low | |
| 6/23/2017 | Deutsche Bank AG | Initiated Coverage | Buy | $79.00 | Low | |
| 6/16/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 5/15/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $79.00 | N/A | |
| 5/3/2017 | Gabelli | Reiterated Rating | Buy | $85.00 | Medium | |
| 5/3/2017 | Barclays PLC | Reiterated Rating | Overweight | $85.00 | Medium | |
| 5/3/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $87.00 | Medium | |
| 5/3/2017 | Maxim Group | Reiterated Rating | Hold | | Low | |
| 4/21/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | | Low | |
| 3/13/2017 | Bank of America Corporation | Reiterated Rating | Neutral | $76.00 -> $68.19 | Low | |
| 3/13/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $70.00 -> $68.00 | Low | |
| 3/1/2017 | Mizuho | Lower Price Target | Buy | $88.00 -> $77.00 | N/A | |
| 2/14/2017 | Berenberg Bank | Set Price Target | Buy | $112.00 -> $78.00 | N/A | |
| 2/8/2017 | Royal Bank Of Canada | Lower Price Target | | $75.00 | N/A | |
| 2/8/2017 | Needham & Company LLC | Reiterated Rating | Hold | | N/A | |
| 2/8/2017 | Citigroup Inc. | Downgrade | Buy -> Neutral | $87.00 -> $76.00 | N/A | |
| 2/8/2017 | Wells Fargo & Company | Reiterated Rating | Market Perform | $79.50 -> $65.50 | N/A | |
| 10/15/2016 | Evercore ISI | Set Price Target | Buy | $90.00 | N/A | |
| 7/29/2016 | Argus | Downgrade | Buy -> Hold | $88.00 -> $81.00 | N/A | |
| 7/27/2016 | S&P Equity Research | Reiterated Rating | Strong-Buy | | N/A | |
| 5/4/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $120.00 -> $116.00 | N/A | |
| 2/3/2016 | Standpoint Research | Initiated Coverage | Buy | $110.00 | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Neutral | $111.00 | N/A | |
| 9/10/2015 | Jyske Bank | Upgrade | Strong-Buy | $125.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Gilead Sciences (NASDAQ:GILD)Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2017 | Q1 2017 | $2.18 | $2.20 | $6.66 billion | $6.51 billion | View | Listen | |
| 2/7/2017 | Q416 | $2.61 | $2.70 | $7.16 billion | $7.30 billion | View | Listen | |
| 11/1/2016 | Q316 | $2.87 | $2.75 | $7.47 billion | $7.40 billion | View | Listen | |
| 7/25/2016 | Q216 | $3.02 | $3.08 | $7.80 billion | $7.78 billion | View | Listen | |
| 4/28/2016 | Q116 | $3.13 | $3.03 | $8.08 billion | $7.80 billion | View | Listen | |
| 2/2/2016 | Q415 | $3.00 | $3.32 | $8.11 billion | $8.51 billion | View | Listen | |
| 10/27/2015 | Q315 | $2.87 | $3.22 | $7.84 billion | $8.30 billion | View | Listen | |
| 7/28/2015 | Q215 | $2.83 | $3.15 | $7.60 billion | $8.22 billion | View | Listen | |
| 4/30/2015 | Q115 | $2.78 | $2.94 | $6.81 billion | $7.59 billion | View | Listen | |
| 2/3/2015 | Q414 | $2.27 | $2.43 | $6.68 million | $7.31 billion | View | Listen | |
| 10/28/2014 | Q314 | $1.92 | $1.84 | $5.99 billion | $6.04 billion | View | Listen | |
| 7/23/2014 | Q214 | $1.61 | $2.36 | $5.68 billion | $6.53 billion | View | Listen | |
| 4/22/2014 | Q114 | $0.75 | $1.48 | $3.80 billion | $5.00 billion | View | Listen | |
| 2/4/2014 | Q413 | $0.50 | $0.55 | $2.85 billion | $3.04 billion | View | Listen | |
| 10/29/2013 | Q313 | $0.48 | $0.52 | $2.72 billion | $2.78 billion | View | Listen | |
| 7/25/2013 | Q2 2013 | $0.50 | $0.50 | $2.66 billion | $2.77 billion | View | Listen | |
| 5/2/2013 | Q1 2013 | $0.50 | $0.48 | $2.57 billion | $2.53 billion | View | Listen | |
| 2/4/2013 | Q4 2012 | $0.48 | $0.50 | $2.43 billion | $2.59 billion | View | Listen | |
| 10/23/2012 | | $0.94 | $1.00 | | | View | N/A | |
| 7/26/2012 | | $0.95 | $0.99 | | | View | N/A | |
| 4/26/2012 | | $0.94 | $0.91 | | | View | N/A | |
| 2/2/2012 | | $1.04 | $0.97 | | | View | N/A | |
| 10/27/2011 | | $1.01 | $1.02 | | | View | N/A | |
| 4/20/2011 | | $0.97 | $0.87 | | | View | N/A | |
| 1/25/2011 | | $0.95 | $0.95 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Gilead Sciences (NASDAQ:GILD)2017 EPS Consensus Estimate: $8.27
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $2.09 | $2.42 | $2.23 |
| Q2 2017 | 3 | $2.01 | $2.29 | $2.15 |
| Q3 2017 | 3 | $1.88 | $2.15 | $1.99 |
| Q4 2017 | 3 | $1.79 | $2.09 | $1.91 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Gilead Sciences (NASDAQ:GILD)| Most Recent Dividend: | 6/29/2017 |
| Annual Dividend: | $2.08 |
| Dividend Yield: | 2.80% |
| Payout Ratio: | 21.99% (Trailing 12 Months of Earnings)
26.07% (Based on This Year's Estimates)
28.97% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/2/2017 | quarterly | $0.52 | 3.09% | 6/14/2017 | 6/16/2017 | 6/29/2017 |
| 2/7/2017 | quarterly | $0.52 | 3.11% | 3/14/2017 | 3/16/2017 | 3/30/2017 |
| 11/1/2016 | quarterly | $0.47 | 2.59% | 12/13/2016 | 12/15/2016 | 12/29/2016 |
| 7/25/2016 | quarterly | $0.47 | 2.32% | 9/14/2016 | 9/16/2016 | 9/29/2016 |
| 4/28/2016 | quarterly | $0.47 | 2.13% | 6/14/2016 | 6/16/2016 | 6/29/2016 |
| 2/2/2016 | quarterly | $0.43 | 1.99% | 3/14/2016 | 3/16/2016 | 3/30/2016 |
| 10/27/2015 | quarterly | $0.43 | 1.59% | 12/14/2015 | 12/16/2015 | 12/30/2015 |
| 7/28/2015 | quarterly | $0.43 | 1.49% | 9/14/2015 | 9/16/2015 | 9/29/2015 |
| 4/30/2015 | quarterly | $0.43 | | 6/12/2015 | 6/16/2015 | 6/29/2015 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 74.05%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/3/2017 | Gregg H Alton | EVP | Sell | 5,000 | $71.06 | $355,300.00 | |
| 7/3/2017 | John C Martin | Insider | Sell | 73,333 | $71.00 | $5,206,643.00 | |
| 5/9/2017 | John Francis Cogan | Director | Sell | 9,943 | $67.25 | $668,666.75 | |
| 4/3/2017 | John C Martin | Insider | Sell | 73,333 | $67.18 | $4,926,510.94 | |
| 3/30/2017 | Gregg H Alton | EVP | Sell | 5,000 | $67.48 | $337,400.00 | |
| 1/3/2017 | John C Martin | Insider | Sell | 73,337 | $73.59 | $5,396,869.83 | |
| 11/18/2016 | John W Madigan | Director | Sell | 105,000 | $74.86 | $7,860,300.00 | |
| 10/3/2016 | John C Martin | Insider | Sell | 100,000 | $77.63 | $7,763,000.00 | |
| 9/22/2016 | Gregg H Alton | EVP | Sell | 5,000 | $81.84 | $409,200.00 | |
| 9/6/2016 | John F Milligan | Insider | Sell | 70,000 | $77.74 | $5,441,800.00 | |
| 9/1/2016 | John C Martin | Insider | Sell | 100,000 | $77.48 | $7,748,000.00 | |
| 8/24/2016 | Kevin E Lofton | Director | Sell | 3,500 | $81.97 | $286,895.00 | |
| 8/1/2016 | John C Martin | Insider | Sell | 100,000 | $80.50 | $8,050,000.00 | |
| 8/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $79.81 | $159,620.00 | |
| 7/5/2016 | John F Milligan | CEO | Sell | 112,000 | $84.33 | $9,444,960.00 | |
| 7/1/2016 | John C Martin | Chairman | Sell | 100,000 | $84.73 | $8,473,000.00 | |
| 7/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $83.12 | $166,240.00 | |
| 6/6/2016 | John F Milligan | CEO | Sell | 112,000 | $86.94 | $9,737,280.00 | |
| 6/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $87.02 | $174,040.00 | |
| 5/2/2016 | John C Martin | Chairman | Sell | 100,000 | $87.82 | $8,782,000.00 | |
| 5/2/2016 | John F Milligan | CEO | Sell | 112,000 | $87.71 | $9,823,520.00 | |
| 5/2/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $88.72 | $177,440.00 | |
| 4/19/2016 | Gregg H Alton | EVP | Sell | 40,000 | $100.01 | $4,000,400.00 | |
| 4/4/2016 | John F Milligan | CEO | Sell | 112,000 | $94.59 | $10,594,080.00 | |
| 4/1/2016 | John C Martin | Chairman | Sell | 100,000 | $93.24 | $9,324,000.00 | |
| 4/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $91.34 | $182,680.00 | |
| 3/14/2016 | Gregg H Alton | EVP | Sell | 5,000 | $90.00 | $450,000.00 | |
| 2/26/2016 | Gayle E Wilson | Director | Sell | 6,650 | $90.61 | $602,556.50 | |
| 2/1/2016 | John C. Martin | CEO | Sell | 100,000 | $83.42 | $8,342,000.00 | |
| 2/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $82.32 | $164,640.00 | |
| 1/4/2016 | John C. Martin | CEO | Sell | 100,000 | $97.68 | $9,768,000.00 | |
| 1/4/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $99.20 | $198,400.00 | |
| 12/15/2015 | Norbert W. Bischofberger | EVP | Sell | 70,000 | $102.41 | $7,168,700.00 | |
| 12/7/2015 | John F. Milligan | COO | Sell | 100,000 | $103.18 | $10,318,000.00 | |
| 11/24/2015 | John Francis Cogan | Director | Sell | 15,000 | $105.95 | $1,589,250.00 | |
| 11/2/2015 | Gregg H. Alton | EVP | Sell | 12,000 | $109.38 | $1,312,560.00 | |
| 11/2/2015 | John C. Martin | CEO | Sell | 150,000 | $109.42 | $16,413,000.00 | |
| 11/2/2015 | Robin L Washington | CFO | Sell | 6,250 | $109.46 | $684,125.00 | |
| 10/27/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | |
| 10/26/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $110.00 | $550,000.00 | |
| 10/26/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | |
| 10/15/2015 | Norbert W. Bischofberger | EVP | Sell | 70,000 | $100.05 | $7,003,500.00 | |
| 10/7/2015 | John F. Milligan | COO | Sell | 100,000 | $99.22 | $9,922,000.00 | |
| 10/5/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $100.00 | $500,000.00 | |
| 10/1/2015 | John C. Martin | CEO | Sell | 150,000 | $97.48 | $14,622,000.00 | |
| 10/1/2015 | Paul Rutherford Carter | EVP | Sell | 2,000 | $98.59 | $197,180.00 | |
| 9/15/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $110.00 | $550,000.00 | |
| 9/15/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | |
| 9/8/2015 | John F. Milligan | COO | Sell | 100,000 | $103.39 | $10,339,000.00 | |
| 9/2/2015 | Robin L Washington | CFO | Sell | 6,250 | $102.20 | $638,750.00 | |
| 9/1/2015 | John C. Martin | CEO | Sell | 150,000 | $102.73 | $15,409,500.00 | |
| 8/28/2015 | Gayle E. Wilson | Director | Sell | 21,000 | $106.96 | $2,246,160.00 | |
| 8/25/2015 | John C. Martin | CEO | Sell | 133,213 | $105.17 | $14,010,011.21 | |
| 8/17/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $116.16 | $8,131,200.00 | |
| 7/7/2015 | John F Milligan | COO | Sell | 100,000 | $114.44 | $11,444,000.00 | |
| 6/26/2015 | John Francis Cogan | Director | Sell | 27,000 | $120.13 | $3,243,510.00 | |
| 6/18/2015 | Paul Rutherford Carter | EVP | Sell | 10,000 | $120.00 | $1,200,000.00 | |
| 6/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $117.67 | $8,236,900.00 | |
| 6/8/2015 | John F Milligan | COO | Sell | 100,000 | $114.05 | $11,405,000.00 | |
| 6/1/2015 | Gregg H Alton | EVP | Sell | 17,000 | $113.64 | $1,931,880.00 | |
| 6/1/2015 | John C Martin | CEO | Sell | 150,000 | $113.95 | $17,092,500.00 | |
| 4/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $103.84 | $7,268,800.00 | |
| 4/8/2015 | Paul Rutherford Carter | EVP | Sell | 1,000 | $100.00 | $100,000.00 | |
| 4/1/2015 | Gregg H Alton | EVP | Sell | 7,000 | $96.53 | $675,710.00 | |
| 4/1/2015 | John C Martin | CEO | Sell | 150,000 | $96.74 | $14,511,000.00 | |
| 3/2/2015 | John C Martin | CEO | Sell | 150,000 | $103.51 | $15,526,500.00 | |
| 3/2/2015 | Paul Rutherford Carter | EVP | Sell | 2,000 | $104.18 | $208,360.00 | |
| 3/2/2015 | Richard James Whitley | Director | Sell | 5,000 | $103.43 | $517,150.00 | |
| 2/6/2015 | Olsen Per Wold | Director | Buy | 10,000 | $99.92 | $999,200.00 | |
| 2/2/2015 | Gregg H Alton | EVP | Sell | 12,000 | $105.73 | $1,268,760.00 | |
| 2/2/2015 | John C Martin | CEO | Sell | 150,000 | $105.43 | $15,814,500.00 | |
| 2/2/2015 | Robin L Washington | CFO | Sell | 33,192 | $105.38 | $3,497,772.96 | |
| 1/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $98.47 | $6,892,900.00 | |
| 1/8/2015 | Gregg H Alton | EVP | Sell | 5,000 | $100.89 | $504,450.00 | |
| 1/5/2015 | John C Martin | CEO | Sell | 150,000 | $95.12 | $14,268,000.00 | |
| 1/2/2015 | Gregg H Alton | EVP | Sell | 7,000 | $95.17 | $666,190.00 | |
| 1/2/2015 | Richard James Whitley | Director | Sell | 5,000 | $95.22 | $476,100.00 | |
| 12/22/2014 | John Francis Cogan | Director | Sell | 26,000 | $95.03 | $2,470,780.00 | |
| 12/8/2014 | John F Milligan | COO | Sell | 146,823 | $106.26 | $15,601,411.98 | |
| 12/1/2014 | John C Martin | CEO | Sell | 140,633 | $100.72 | $14,164,555.76 | |
| 12/1/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $100.02 | $200,040.00 | |
| 11/3/2014 | John C Martin | CEO | Sell | 140,625 | $110.40 | $15,525,000.00 | |
| 11/3/2014 | Richard James Whitley | Director | Sell | 5,000 | $112.02 | $560,100.00 | |
| 11/3/2014 | Robin L Washington | CFO | Sell | 33,192 | $110.26 | $3,659,749.92 | |
| 10/24/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $110.00 | $220,000.00 | |
| 10/7/2014 | John F Milligan | COO | Sell | 146,895 | $104.60 | $15,365,217.00 | |
| 10/1/2014 | John C Martin | CEO | Sell | 140,625 | $105.91 | $14,893,593.75 | |
| 10/1/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $106.39 | $212,780.00 | |
| 10/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $106.99 | $534,950.00 | |
| 9/26/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $107.47 | $214,940.00 | |
| 9/22/2014 | John Francis Cogan | Director | Sell | 5,000 | $106.60 | $533,000.00 | |
| 9/8/2014 | John F Milligan | COO | Sell | 146,895 | $105.99 | $15,569,401.05 | |
| 9/2/2014 | Gregg H Alton | EVP | Sell | 33,000 | $108.58 | $3,583,140.00 | |
| 9/2/2014 | John C Martin | CEO | Sell | 140,625 | $108.64 | $15,277,500.00 | |
| 8/26/2014 | Paul Rutherford Carter | EVP | Sell | 10,000 | $106.16 | $1,061,600.00 | |
| 8/25/2014 | Robin L Washington | CFO | Sell | 4,304 | $105.87 | $455,664.48 | |
| 8/21/2014 | John Francis Cogan | Director | Sell | 5,000 | $101.09 | $505,450.00 | |
| 8/14/2014 | Robin L Washington | CFO | Sell | 33,556 | $95.56 | $3,206,611.36 | |
| 8/1/2014 | Gregg H Alton | EVP | Sell | 33,000 | $91.62 | $3,023,460.00 | |
| 8/1/2014 | John C Martin | CEO | Sell | 140,625 | $91.53 | $12,871,406.25 | |
| 8/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $91.00 | $455,000.00 | |
| 8/1/2014 | Robin L Washington | CFO | Sell | 30,600 | $91.48 | $2,799,288.00 | |
| 7/28/2014 | Nicholas G Moore | Director | Sell | 45,000 | $90.56 | $4,075,200.00 | |
| 7/21/2014 | John Francis Cogan | Director | Sell | 5,000 | $89.67 | $448,350.00 | |
| 7/8/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $86.45 | $1,446,135.60 | |
| 7/1/2014 | Gregg H Alton | EVP | Sell | 33,000 | $84.12 | $2,775,960.00 | |
| 7/1/2014 | John C Martin | CEO | Sell | 140,625 | $84.84 | $11,930,625.00 | |
| 7/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $83.65 | $418,250.00 | |
| 6/30/2014 | Robin L Washington | CFO | Sell | 10,400 | $83.98 | $873,392.00 | |
| 6/23/2014 | John Francis Cogan | Director | Sell | 5,000 | $81.82 | $409,100.00 | |
| 6/16/2014 | Norbert W Bischofberger | EVP | Sell | 90,000 | $80.90 | $7,281,000.00 | |
| 6/9/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $79.43 | $1,328,705.04 | |
| 6/4/2014 | Robin L Washington | CFO | Sell | 6,426 | $82.52 | $530,273.52 | |
| 6/2/2014 | Gregg H Alton | EVP | Sell | 33,000 | $81.35 | $2,684,550.00 | |
| 6/2/2014 | Richard James Whitley | Director | Sell | 5,000 | $80.95 | $404,750.00 | |
| 5/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $80.65 | $7,258,500.00 | |
| 5/6/2014 | Robin Washington | CFO | Sell | 3,000 | $79.91 | $239,730.00 | |
| 5/1/2014 | Gregg Alton | EVP | Sell | 13,000 | $79.08 | $1,028,040.00 | |
| 5/1/2014 | John Martin | CEO | Sell | 140,625 | $79.02 | $11,112,187.50 | |
| 5/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $78.63 | $393,150.00 | |
| 5/1/2014 | Robin Washington | CFO | Sell | 27,600 | $79.16 | $2,184,816.00 | |
| 4/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $67.03 | $6,032,700.00 | |
| 4/8/2014 | John Francis Cogan | Director | Sell | 5,000 | $70.55 | $352,750.00 | |
| 4/8/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $70.53 | $1,179,825.84 | |
| 4/1/2014 | Gregg Alton | EVP | Sell | 13,000 | $73.20 | $951,600.00 | |
| 4/1/2014 | John Martin | CEO | Sell | 140,625 | $73.26 | $10,302,187.50 | |
| 3/14/2014 | John Francis Cogan | Director | Sell | 14,000 | $76.44 | $1,070,160.00 | |
| 3/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $75.89 | $6,830,100.00 | |
| 3/10/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $79.32 | $1,326,864.96 | |
| 3/3/2014 | Gregg Alton | EVP | Sell | 33,000 | $81.84 | $2,700,720.00 | |
| 3/3/2014 | John Martin | CEO | Sell | 140,625 | $81.74 | $11,494,687.50 | |
| 2/26/2014 | Nicholas Moore | Director | Sell | 20,000 | $84.05 | $1,681,000.00 | |
| 2/19/2014 | Nicholas Moore | Director | Sell | 19,068 | $83.12 | $1,584,932.16 | |
| 1/23/2014 | Kevin Young | EVP | Sell | 100,000 | $81.44 | $8,144,000.00 | |
| 1/21/2014 | Gregg Alton | EVP | Sell | 120,000 | $80.00 | $9,600,000.00 | |
| 1/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $74.23 | $6,680,700.00 | |
| 10/23/2013 | Kevin Young | EVP | Sell | 75,000 | $68.56 | $5,142,000.00 | |
| 10/14/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $62.54 | $5,628,600.00 | |
| 9/23/2013 | Kevin Young | EVP | Sell | 100,000 | $62.88 | $6,288,000.00 | |
| 9/16/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $63.11 | $5,679,900.00 | |
| 9/3/2013 | Gregg Alton | EVP | Sell | 30,000 | $60.99 | $1,829,700.00 | |
| 9/3/2013 | John Martin | CEO | Sell | 282,242 | $60.97 | $17,208,294.74 | |
| 8/30/2013 | Nicholas Moore | Director | Sell | 151,720 | $60.42 | $9,166,922.40 | |
| 8/14/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $58.77 | $5,289,300.00 | |
| 8/1/2013 | Gregg H Alton | EVP | Sell | 30,000 | $61.49 | $1,844,700.00 | |
| 8/1/2013 | John C Martin | CEO | Sell | 282,242 | $61.61 | $17,388,929.62 | |
| 7/30/2013 | John W Madigan | Director | Sell | 249,000 | $61.97 | $15,430,530.00 | |
| 7/15/2013 | Norbert W Bischofberger | EVP | Sell | 90,000 | $57.33 | $5,159,700.00 | |
| 7/2/2013 | John Francis Cogan | Director | Sell | 17,000 | $51.66 | $878,220.00 | |
| 7/1/2013 | Gregg H Alton | EVP | Sell | 30,000 | $52.09 | $1,562,700.00 | |
| 7/1/2013 | John C Martin | CEO | Sell | 282,242 | $52.00 | $14,676,584.00 | |
| 7/1/2013 | Robin L Washington | CFO | Sell | 45,600 | $52.01 | $2,371,656.00 | |
| 6/7/2013 | John Francis Cogan | Director | Sell | 110,000 | $52.15 | $5,736,500.00 | |
| 6/3/2013 | Gregg H Alton | EVP | Sell | 30,000 | $52.77 | $1,583,100.00 | |
| 6/3/2013 | John C Martin | CEO | Sell | 282,242 | $52.84 | $14,913,667.28 | |
| 2/28/2013 | Olsen Per Wold | Director | Buy | 10,000 | $43.05 | $430,500.00 | |
| 12/3/2012 | Gregg H Alton | EVP | Sell | 44,000 | $75.10 | $3,304,400.00 | |
| 12/3/2012 | John C Martin | CEO | Sell | 291,000 | $75.01 | $21,827,910.00 | |
| 11/12/2012 | Robin L Washington | CFO | Sell | 55,950 | $73.11 | $4,090,504.50 | |
| 10/3/2012 | John F Milligan | COO | Sell | 140,000 | $69.85 | $9,779,000.00 | |
| 10/2/2012 | Robin L Washington | CFO | Sell | 29,500 | $68.62 | $2,024,290.00 | |
| 9/4/2012 | Gregg H Alton | EVP | Sell | 44,000 | $57.50 | $2,530,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
| Source: |
|
| Date | Headline |
|---|
 | Gilead Sciences' (NASDAQ:GILD) "Hold" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - July 25 at 12:12 PM |
 | 3 Dividend Stocks That Thrive in Bear Markets
www.fool.com - July 25 at 7:52 AM |
 | Gilead Sciences (GILD) Reports Phase 3 Results for Investigational Fixed-Dose ...
www.streetinsider.com - July 25 at 1:46 AM |
 | Recent Buy: Gilead Sciences
seekingalpha.com - July 25 at 1:46 AM |
 | J.P. Morgan Comments on Gilead Sciences, Inc. (GILD) Following Clinical Results in HIV
finance.yahoo.com - July 25 at 1:46 AM |
| I Think Gilead Is Worth More than $86 Per Share - Seeking Alpha
seekingalpha.com - July 24 at 8:44 PM |
 | Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care - MarketWatch
www.marketwatch.com - July 24 at 8:44 PM |
| Gilead Sciences: There's Always Safety
finance.yahoo.com - July 24 at 8:44 PM |
| 3 Things You Can Expect in Gilead Sciences' Q2 Update
finance.yahoo.com - July 24 at 8:44 PM |
| Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials
finance.yahoo.com - July 24 at 8:44 PM |
 | Gilead Sciences, Inc. (GILD) Stock Is a 2-for-1 Deal
investorplace.com - July 24 at 12:31 PM |
| Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
finance.yahoo.com - July 24 at 9:07 AM |
| Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care
finance.yahoo.com - July 24 at 9:07 AM |
| The Worm Has Turned in Biotech's Favor
finance.yahoo.com - July 23 at 6:32 PM |
| Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
www.fool.com - July 22 at 11:55 AM |
| BMO Capital Markets Reaffirms "Hold" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 22 at 11:34 AM |
 | Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter? - Barron's
www.barrons.com - July 22 at 12:24 AM |
| Take Profits On Gilead - Seeking Alpha
seekingalpha.com - July 20 at 4:51 PM |
| Is Gilead (GILD) Poised for a Beat This Earnings Season?
finance.yahoo.com - July 20 at 4:51 PM |
| Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX)
finance.yahoo.com - July 20 at 4:51 PM |
| Vertex Becomes an Overnight Biotech M&A Darling
finance.yahoo.com - July 20 at 4:51 PM |
| When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
finance.yahoo.com - July 20 at 12:46 AM |
| Gilead Sciences' Shares Just Answered The Question - Seeking Alpha
seekingalpha.com - July 19 at 7:43 PM |
| Q4 2017 Earnings Estimate for Gilead Sciences, Inc. (GILD) Issued By Leerink Swann
www.americanbankingnews.com - July 19 at 12:21 PM |
| Gilead Sciences (GILD) Vosevi Approved by FDA; Has Black Box Warning on Risk of HBV Reactivation
www.streetinsider.com - July 19 at 1:35 AM |
 | Agree To Purchase Gilead Sciences At $40, Earn 2.5% Using Options
www.nasdaq.com - July 19 at 1:35 AM |
| U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
finance.yahoo.com - July 19 at 1:35 AM |
| Gilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment
finance.yahoo.com - July 19 at 1:35 AM |
| FDA approves Gilead's drug for chronic hep C patients
finance.yahoo.com - July 19 at 1:35 AM |
| Vertex shares soar 24% to all-time high on cystic fibrosis drug studies - MarketWatch
www.marketwatch.com - July 18 at 8:33 PM |
| Q2 2017 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Increased by Analyst
www.americanbankingnews.com - July 18 at 9:21 AM |
| 5 Ways Gilead Sciences Could Spend Its Cash Hoard
www.fool.com - July 18 at 8:46 AM |
| 9 Reasons Gilead Will Not Acquire Incyte - Seeking Alpha
seekingalpha.com - July 17 at 7:57 PM |
| Gilead Sciences, Inc. (NASDAQ:GILD) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:28 PM |
| Will the Drug Pricing Executive Order Help Big Pharma?
finance.yahoo.com - July 17 at 11:47 AM |
| How Intangible Assets Create Value
finance.yahoo.com - July 17 at 11:47 AM |
| These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
finance.yahoo.com - July 16 at 6:09 PM |
| Gilead (GILD) Application for HIV Drug Validated in EU - Yahoo Finance
finance.yahoo.com - July 16 at 11:01 AM |
| Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Announce Quarterly Sales of $6.35 Billion
www.americanbankingnews.com - July 15 at 8:04 AM |
| Short Interest in Gilead Sciences, Inc. (GILD) Expands By 15.7%
www.americanbankingnews.com - July 15 at 7:22 AM |
| [$$] "A Great Time" to Invest in the Health-Care Sector
finance.yahoo.com - July 15 at 1:03 AM |
| The Acquisition That Could Put Gilead Over $100 - Barron's
www.barrons.com - July 14 at 7:57 PM |
| European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
finance.yahoo.com - July 13 at 10:31 PM |
| Robert W. Baird Reiterates "Outperform" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 13 at 8:28 PM |
| Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Earnings of $2.08 Per Share
www.americanbankingnews.com - July 13 at 6:30 PM |
| Another Reason To Buy Gilead - Seeking Alpha
seekingalpha.com - July 13 at 4:15 PM |
| 5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
finance.yahoo.com - July 13 at 4:15 PM |
| Brokers Offer Predictions for Gilead Sciences, Inc.'s Q2 2017 Earnings (NASDAQ:GILD)
www.americanbankingnews.com - July 13 at 10:00 AM |
| Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
finance.yahoo.com - July 12 at 7:44 PM |
| Jefferies Group LLC Reaffirms Hold Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 11 at 8:59 AM |
Gilead Sciences (GILD) Chart for Tuesday, July, 25, 2017
